Collegium Pharmaceutical (COLL) Long-Term Deferred Tax (2021 - 2026)

Collegium Pharmaceutical's Long-Term Deferred Tax history runs 6 years deep, the most recent figure standing at $113.6 million for Q1 2026.

• In Q1 2026, Long-Term Deferred Tax rose 23.89% year-over-year to $113.6 million; the TTM figure through Mar 2026 stood at $113.6 million (up 23.89% YoY), while the FY2025 annual figure was $112.5 million, up 14.8% from the prior year.
• Long-Term Deferred Tax was $113.6 million for Q1 2026 at Collegium Pharmaceutical, up from $112.5 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $113.6 million in Q1 2026 to a low of $24.0 million in Q4 2022.
• Historically, Long-Term Deferred Tax has averaged $56.0 million across 5 years, with a median of $30.7 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax slumped 69.31% in 2022, then soared 273.33% in 2024.
• A 5-year view of Long-Term Deferred Tax shows it stood at $24.0 million in 2022, then grew by 9.64% to $26.3 million in 2023, then jumped by 273.33% to $98.0 million in 2024, then gained by 14.8% to $112.5 million in 2025, then climbed by 0.91% to $113.6 million in 2026.
• The last three Long-Term Deferred Tax figures came in at $113.6 million (Q1 2026), $112.5 million (Q4 2025), and $102.5 million (Q3 2025), per Business Quant data.